Skip to main content
. 2018 Oct 26;8:15841. doi: 10.1038/s41598-018-33960-4

Figure 3.

Figure 3

Partial inhibition of TLR4 activation in moDC exposed to ssON 35 PS. (A) Schematic view of TLR4-mediated cell signaling. Human moDC were exposed to the TLR4 agonist LPS with or without ssON 35 PS. (B) 0.5 µM ssON 35 PS inhibited uptake of fluorescently labelled LPS-Alexa488. Histograms show representative data from at least three donors. Dark green histogram is without ssON. Lighter color with a dashed lines depicts the addition of ssON. Grey displays background (fluorescent signal at +4 °C). (C) Quantitative analysis of LPS uptake measured by flow cytometry in the presence of 0.5 µM ssON 35 PS at +37 °C or +4 °C. (D) Wide-field microscopy of uptake of fluorescent LPS-Alexa488 in moDC (E) in the presence of 0.5 µM ssON 35 PS. (F,G) 0.5 µM ssON 35 PS had no influence on secretion of cytokines/chemokines that are downstream of NF-κB-mediated signaling pathways (IL-6 and IL-10). (H,I) 0.5 µM ssON 35 PS reduced secretion of cytokines/chemokines that are downstream of TRIF mediated signaling pathways (IL-29 and CXCL10). All data are from at least three donors in duplicate. Error bars are given in SEM. Non-parametric Mann-Whitney test was used to compare the data. P-value: not significant (n.s) P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.